证券代码：000931 证券简称：中关村 公告编号：2025-094 北京中关村科技发展（控股）股份有限公司 第九届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）第九届监事 会第三次会议通知于 2025 年 8 月 15 日以专人送达、电子邮件或传真等方式发出， 会议于 2025 年 8 月 25 日下午 14 时在北京市朝阳区霄云路 26 号鹏润大厦 B 座 22 层 1 号会议室以现场表决方式如期召开。会议应到监事 3 名，实到监事 3 名。 会议召开程序符合相关法律法规和《公司章程》的有关规定。经与会监事认真讨 论研究，形成以下决议： 第九届监事会第三次会议决议公告 共 2 页 一、审议通过《2025 年半年度报告全文及摘要》； 表决结果：3 票同意，0 票反对，0 票弃权。 具体内容详见与本公告同日披露的《2025 年半年度报告》《2025 年半年度 报告摘要》（公告编号：2025-095、096）。 二、审议通过《监事会对<2025 年半年度报告全文及摘要>的审核意见 ...

第九届董事会第三次会议决议决议公告 共 4 页 证券代码：000931 证券简称：中关村 公告编号：2025-093 北京中关村科技发展（控股）股份有限公司 第九届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）第九届董事 会第三次会议通知于 2025 年 8 月 15 日以专人送达、电子邮件或传真等方式发出， 会议于 2025 年 8 月 25 日上午 10 时在北京市朝阳区霄云路 26 号鹏润大厦 B 座 22 层 1 号会议室以现场结合通讯表决方式如期召开。会议应到董事 9 名，实到 董事 9 名。会议召开程序符合相关法律法规和《公司章程》的有关规定。经与会 董事认真讨论研究，形成以下决议： 一、审议通过《2025 年半年度报告全文及摘要》； 表决结果：9 票同意，0 票反对，0 票弃权。 全体参会董事审议通过公司《2025 年半年度报告》全文及摘要，没有董事 对 2025 年半年度报告内容的真实性、准确性和完整性无法保证或存在异议。 《2025 年半年度财务报告》已经董事 ...

北京中关村科技发展（控股）股份有限公司 2025 年半年度报告全文 共 177 页 北京中关村科技发展（控股）股份有限公司 二〇二五年八月 1 北京中关村科技发展（控股）股份有限公司 2025 年半年度报告全文 共 177 页 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人许钟民、主管会计工作负责人宋学武及会计机构负责人（会 计主管人员）黄瑛声明：保证本半年度报告中财务报告的真实、准确、完 整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承 诺，敬请投资者注意投资风险。 2025 年半年度报告 2025-095 公司请投资者认真阅读本半年度报告全文。公司在本报告第三节"管理层 讨论与分析"中"十、公司面临的风险和应对措施"部分描述了公司未来经 营中可能面临的风险以及应对措施，敬请广大投资者注意查阅。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 ...

Group 1 - The event themed "The Future is Here: Advanced Therapies and Precision Medicine Paving the Way for Cures" successfully attracted over 70 participants from partner organizations and member units [1] - Recent advancements in therapies such as chemical drugs, CD38 monoclonal antibodies, CAR-T, and bispecific antibodies are paving the way for curing patients [3] - 2025 is identified as a critical year for precision medicine, with significant developments expected in innovative drugs, standardized diagnosis and treatment, hospital management, and medical insurance [3] Group 2 - The event featured notable speakers, including the chairman of Huimei Extreme Medical and the chairman of the organizing company, who emphasized the importance of innovation in the medical field [5] - The Vice President of the Chinese Hospital Association highlighted the achievements in cancer prevention and treatment, aiming for a 46.6% five-year survival rate for cancer by 2030 [7] - The first prescription for stem cell drugs in China was issued in June 2025, marking a significant step towards commercialization in clinical settings [7] Group 3 - The "Beijing Plan" for haploidentical stem cell transplantation has been recognized as a breakthrough in leukemia treatment, achieving a survival rate of 75%-86% [8] - The plan has been adopted globally and is included in authoritative textbooks, showcasing China's advancements in hematological malignancies [8] - The event underscored the necessity of financial support for technological innovations in the medical field, with Beijing Bank positioning itself as a key player in this ecosystem [11] Group 4 - A roundtable discussion featured experts from various fields discussing the current state and challenges of precision medicine in China, providing valuable insights for future development [13] - The event aimed to leverage the advantages of the Zhongguancun Forum membership system to foster collaboration and resource integration in advanced therapies and precision medicine [13]

Core Viewpoint - Zhongguancun Science and Technology Leasing (01601) has entered into a financing lease agreement with Henan Baichuan Changyin Environmental Energy Co., Ltd., involving a total transaction value of approximately RMB 30 million for leasing assets [1] Group 1: Financing Lease Agreement - The company will purchase leasing assets from the lessee for RMB 30 million [1] - The leasing assets consist of tank containers [1] - The lease term is set for 36 months, with total lease payments amounting to approximately RMB 32.62 million [1]

Group 1 - The company, Zhongguancun Technology Leasing (01601), announced a financing lease agreement with Henan Baichuan Changyin Environmental Energy Co., Ltd. (300614) [1] - The total transfer price for the leased asset is RMB 30 million, with a total lease payment of approximately RMB 32.6195 million over a lease term of 36 months [1] - The leased asset is a tank container [1]

天眼查商业履历信息显示，北京中关村科技发展(控股)股份有限公司，成立于1999年，位于北京市，是 一家以从事医药制造业为主的企业。企业注册资本75312.6982万人民币，实缴资本75312.6982万人民 币。公司法定代表人为许钟民。 通过天眼查大数据分析，北京中关村科技发展(控股)股份有限公司共对外投资了24家企业，参与招投标 项目6次，知识产权方面有商标信息139条，此外企业还拥有行政许可13个。 来源：金融界 金融界消息 截至2025年8月25日收盘，中 关 村（000931）报收于5.61元，上涨2.0%，换手率3.41%，成 交量25.60万手，成交金额1.42亿元。 资金流向方面，今日主力资金净流入1360.38万元，占比成交额9.56%。其中，超大单净流入1190.66万 元、占成交额8.36%，大单净流入169.72万元、占成交额1.19%，中单净流出流出1018.00万元、占成交 额7.15%，小单净流出342.38万元、占成交额2.4%。 中关村最新一期业绩显示，截至2025一季报，公司营业总收入6.16亿元、同比增长1.63%，归属净利润 1575.64万元，同比增长35.47%，扣非 ...

Core Viewpoint - The announcement highlights that Shandong Huasu Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration (NMPA) for the marketing of Succinic Acid Metoprolol raw materials, which is expected to enhance the company's market competitiveness and operational performance [1][3]. Group 1: Approval Details - The chemical raw material approved is Succinic Acid Metoprolol, with the application number CYHS2460273 and notification number 2025YS00723 [1]. - The approval indicates that the product meets the relevant requirements for drug registration as per the Drug Administration Law of the People's Republic of China [1]. Group 2: Product Background - Succinic Acid Metoprolol is a selective β1-adrenergic receptor blocker, initially developed in 1969, used clinically for treating hypertension, angina, and heart failure [2]. - There are currently 16 manufacturers listed for Succinic Acid Metoprolol raw materials, with 12 classified as "A" status and 4 as "I" status according to the CDE raw and auxiliary material registration information platform [2]. Group 3: Impact on the Company - The approval of Succinic Acid Metoprolol provides a stable raw material source for the company's ongoing research into sustained-release capsules, thereby enhancing the competitiveness of related products [3]. - The company emphasizes the importance of drug research and development, maintaining strict quality control throughout the drug development, manufacturing, and sales processes [3].

Core Viewpoint - The announcement from Zhongguancun indicates that its subsidiary, Shandong Huasu Pharmaceutical Co., has received approval from the National Medical Products Administration for the marketing application of the raw material drug Succinic Acid Metoprolol [2] Group 1 - Zhongguancun will disclose the consistency evaluation application for Naloxone Injection and the marketing application for Succinic Acid Metoprolol raw material drug by March 2024 [2] - Shandong Huasu's Succinic Acid Metoprolol raw material drug has passed the technical review by the National Medical Products Administration's Drug Evaluation Center [2] - The company has received the "Approval Notice for Chemical Raw Material Drug Marketing Application" issued by the National Medical Products Administration [2]

关于下属公司山东华素琥珀酸美托洛尔原料药获批上市的公告 共 2 页 证券代码：000931 证券简称：中关村 公告编号：2025-092 北京中关村科技发展（控股）股份有限公司 关于下属公司山东华素琥珀酸美托洛尔原料药获批上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）于 2024 年 3 月披露《关于下属公司北京华素盐酸纳洛酮注射液一致性评价申报和山东华素琥 珀酸美托洛尔原料药申报收到国家药监局<受理通知书>的公告》（公告编号： 2024-025）。 近日，公司下属公司山东华素制药有限公司（以下简称：山东华素）"琥珀 酸美托洛尔原料药"于近日通过国家药品监督管理局药品审评中心（以下简称： CDE）技术审评，并获得国家药品监督管理局（以下简称：国家药监局）核准签 发的《化学原料药上市申请批准通知书》。现将具体情况公告如下： 一、批件主要内容 化学原料药名称：琥珀酸美托洛尔 申请事项：境内生产化学原料药上市申请 受理号：CYHS2460273 通知书编号：2025YS00723 生产企业：山东华 ...